Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Darktrace following Q3 results

(Sharecast News) - Analysts at Berenberg raised their target price on software and services firm Darktrace from 600.0p to 630.0p on Thursday after the group's third-quarter results earlier this morning demonstrated a continuation of "strong momentum" seen in Q2.

Berenberg noted that annualised recurring revenues had grown 23.5% year-on-year to $731.1m, with $29.0m of net annual recurring revenues added in the quarter - up 6.2% year-on-year.

"We think that this is particularly significant within the context of negative yoy changes in net ARR added in Q1 (-22%) and Q2 (-4%)," said Berenberg, which has a 'buy' rating on the stock.

The German bank added that the company also upgraded its growth and margin outlook for the third time in three months, leading the analysts to increase its ARR, revenue and adjusted underlying earnings forecasts in response.

"In our view, Darktrace remains poised to outperform, given: a) its ongoing potential to exceed growth and margin expectations; b) that it has sufficient growth and operating leverage to drive a c30% FY23- FY26 CAGR in free cash flow per share; and c) the fact that it warrants a multiple rerating - at 4.4x CY24 EV/sales, it trades at a c60% CY24 EV/sales discount to US peers," said Berenberg.

"Darktrace trades on 4.4x CY24 EV/sales, c60% below our US peer group, despite similar expected sales growth and higher expected margins."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Goldman Sachs downgrades SSP to 'sell', prefers WH Smith
(Sharecast News) - Goldman Sachs downgraded SSP on Monday to 'sell' from 'neutral' "on a relative basis" as it took a look at European travel concessions.
UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.